homoharringtonine has been researched along with Leukemia--Myelomonocytic--Chronic* in 1 studies
1 trial(s) available for homoharringtonine and Leukemia--Myelomonocytic--Chronic
| Article | Year |
|---|---|
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
The outcome of patients with myelodysplastic syndromes (MDSs) after failure of hypomethylating agents (HMAs) failure is poor with a median overall survival (OS) of only 4-6 months. Omacetaxine mepesuccinate (OM) is safe and effective in myeloid malignancies but has not been studied in MDS with HMA failure. We conducted a phase II study of OM in patients with MDS or chronic myelomonocytic leukemia (CMML) who had previously failed or been intolerant to HMAs. Patients received OM at a dose of 1.25 mg/m Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Substitution; Fatigue; Febrile Neutropenia; Female; Gastrointestinal Diseases; Hemorrhage; Homoharringtonine; Humans; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes | 2019 |